

Alex C Spyropoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3916166/publications.pdf>

Version: 2024-02-01

161
papers

17,411
citations

50566

48
h-index

15698

129
g-index

163
all docs

163
docs citations

163
times ranked

18179
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 409-421. | 1.9 | 17 |
| 2 | Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 532-535. | 1.9 | 7 |
| 3 | Studying the coagulopathy of COVID-19. <i>Lancet, The</i> , 2022, 399, 118-119. | 6.3 | 25 |
| 4 | Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?. <i>European Journal of Internal Medicine</i> , 2022, 96, 13-16. | 1.0 | 9 |
| 5 | Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 209, 94-98. | 0.8 | 34 |
| 6 | Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 50-59. | 6.3 | 172 |
| 7 | State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1279-1287. | 1.8 | 11 |
| 8 | Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. <i>Circulation</i> , 2022, 145, 1471-1479. | 1.6 | 6 |
| 9 | Comparison of Guidelines for Evaluation of Suspected Pulmonary Embolism in Pregnancy. <i>Chest</i> , 2022, 161, 1628-1641. | 0.4 | 2 |
| 10 | Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization. <i>Journal of the American Heart Association</i> , 2022, 11, e025342. | 1.6 | 0 |
| 11 | ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225. | 1.9 | 100 |
| 12 | Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. <i>TH Open</i> , 2022, 06, e177-e183. | 0.7 | 1 |
| 13 | Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236. | 1.9 | 23 |
| 14 | Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients. <i>Expert Review of Hematology</i> , 2022, 15, 597-605. | 1.0 | 6 |
| 15 | Using big data to retrospectively validate the COMPASS-CAT risk assessment model: considerations on methodology. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 12-16. | 1.0 | 2 |
| 16 | Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. <i>International Journal of Hematology</i> , 2021, 113, 330-336. | 0.7 | 16 |
| 17 | Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1043-1053. | 1.8 | 55 |
| 18 | Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 308-315. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 296-300. | 1.0 | 34 |
| 20 | Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. <i>Journal of the American Heart Association</i> , 2021, 10, e019459. | 1.6 | 30 |
| 21 | Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 897-901. | 1.0 | 39 |
| 22 | Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1684-1695. | 1.8 | 7 |
| 23 | Prognostic Value of Venous Thromboembolism Risk Assessment Models in Patients with Severe COVID-19. <i>TH Open</i> , 2021, 05, e211-e219. | 0.7 | 8 |
| 24 | Sex-Based Differences in COVID-19 Outcomes. <i>Journal of Women's Health</i> , 2021, 30, 492-501. | 1.5 | 17 |
| 25 | Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , 2021, 235, 12-23. | 1.2 | 36 |
| 26 | Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. <i>Blood</i> , 2021, 137, 2838-2847. | 0.6 | 133 |
| 27 | Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12520. | 1.0 | 27 |
| 28 | The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007. | 1.8 | 21 |
| 29 | External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1032-1035. | 1.0 | 21 |
| 30 | Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12547. | 1.0 | 1 |
| 31 | Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2772-2780. | 1.9 | 4 |
| 32 | Medically Ill hospitalized Patients for COVID-19 Thrombosis Extended Prophylaxis with rivaroxaban Therapy: Rationale and Design of the MICHELLE Trial. <i>American Heart Journal</i> , 2021, 242, 115-122. | 1.2 | 18 |
| 33 | Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1612. | 2.6 | 326 |
| 34 | A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 159-167. | 1.0 | 5 |
| 35 | Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110533. | 0.7 | 2 |
| 36 | Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. <i>Journal of the American Heart Association</i> , 2021, 10, e021579. | 1.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | The HEP-COVID Trial. <i>Heart International</i> , 2021, 15, 62. | 0.4 | 1 |
| 38 | Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. <i>Annals of Emergency Medicine</i> , 2020, 76, 470-485. | 0.3 | 46 |
| 39 | Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 316-320. | 1.0 | 10 |
| 40 | Heparin Bridging Therapy for Patients on Chronic Oral Anticoagulants in Periprocedural Settings. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 026-031. | 1.5 | 8 |
| 41 | Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. <i>Journal of the American Heart Association</i> , 2020, 9, e017316. | 1.6 | 18 |
| 42 | Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study. <i>TH Open</i> , 2020, 04, e255-e262. | 0.7 | 2 |
| 43 | Hospitalized COVID-19 Patients and Venous Thromboembolism. <i>Circulation</i> , 2020, 142, 129-132. | 1.6 | 50 |
| 44 | The underrecognized prothrombotic vascular disease of COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 942-943. | 1.0 | 2 |
| 45 | Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , 2020, 4, 3520-3527. | 2.5 | 38 |
| 46 | Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962092591. | 0.7 | 4 |
| 47 | Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2958-2967. | 1.9 | 98 |
| 48 | The management of venous thromboembolism in hospitalized patients with COVID-19. <i>Blood Advances</i> , 2020, 4, 4028-4028. | 2.5 | 14 |
| 49 | Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628. | 1.8 | 131 |
| 50 | Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. <i>Blood</i> , 2020, 135, 1788-1810. | 0.6 | 73 |
| 51 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024. | 1.8 | 206 |
| 52 | Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1859-1865. | 1.9 | 547 |
| 53 | Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3140-3147. | 1.2 | 50 |
| 54 | Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020, 120, 924-936. | 1.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 562-568. | 1.0 | 19 |
| 56 | Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. <i>TH Open</i> , 2020, 04, e59-e65. | 0.7 | 104 |
| 57 | Comparison of international societal guidelines for the diagnosis of suspected pulmonary embolism during pregnancy. <i>Lancet Haematology</i> , 2020, 7, e247-e258. | 2.2 | 28 |
| 58 | Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. <i>Thrombosis and Haemostasis</i> , 2020, 120, 515-524. | 1.8 | 16 |
| 59 | External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model. <i>Oncologist</i> , 2020, 25, e1083-e1090. | 1.9 | 19 |
| 60 | Hospital-based use of thromboprophylaxis in patients with COVID-19. <i>Lancet, The</i> , 2020, 395, e75. | 6.3 | 40 |
| 61 | Emergence of institutional antithrombotic protocols for coronavirus 2019. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 510-517. | 1.0 | 44 |
| 62 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973. | 1.2 | 2,392 |
| 63 | New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1002. | 1.0 | 12 |
| 64 | Thromboembolic Outcomes of Hospitalized COVID-19 Patients in the 90-Day Post-Discharge Period: Early Data from the Northwell CORE-19 Registry. <i>Blood</i> , 2020, 136, 33-34. | 0.6 | 5 |
| 65 | Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant—Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 333. | 2.6 | 0 |
| 66 | Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. <i>TH Open</i> , 2020, 04, e344-e350. | 0.7 | 0 |
| 67 | Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1966-1972. | 1.9 | 70 |
| 68 | Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469. | 2.6 | 283 |
| 69 | Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. <i>Thrombosis Research</i> , 2019, 182, 159-166. | 0.8 | 48 |
| 70 | Quality metrics of warfarin initiation in hospitalized older adults. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 459-465. | 1.0 | 0 |
| 71 | Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 570-579. | 1.0 | 3 |
| 72 | Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3256-3262. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985089. | 0.7 | 17 |
| 74 | Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. <i>American Heart Journal</i> , 2019, 212, 113-119. | 1.2 | 70 |
| 75 | Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 184, 58-61. | 0.8 | 14 |
| 76 | Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988602. | 0.7 | 51 |
| 77 | External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18005-e18005. | 0.8 | 2 |
| 78 | Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 575-582. | 0.7 | 18 |
| 79 | Extended thromboprophylaxis in the acutely ill medical patient after hospitalization – a paradigm shift in post-discharge thromboprophylaxis. <i>Hospital Practice (1995)</i> , 2018, 46, 5-15. | 0.5 | 9 |
| 80 | Direct oral anticoagulants in the treatment of pulmonary embolism. <i>Current Medical Research and Opinion</i> , 2018, 34, 131-140. | 0.9 | 12 |
| 81 | Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 2279-2280. | 13.9 | 2 |
| 82 | Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 813-822. | 1.5 | 7 |
| 83 | Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1402-1411. | 1.6 | 26 |
| 84 | Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127. | 13.9 | 205 |
| 85 | Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis. <i>JMIR MHealth and UHealth</i> , 2018, 6, e11090. | 1.8 | 7 |
| 86 | A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. <i>Oncologist</i> , 2017, 22, 1222-1231. | 1.9 | 167 |
| 87 | Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 532-541. | 0.7 | 10 |
| 88 | The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017, 01, e56-e65. | 0.7 | 94 |
| 89 | The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2415-2424. | 1.8 | 62 |
| 90 | New paradigms in venous thromboprophylaxis of medically ill patients. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1662-1670. | 1.8 | 44 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 544-553. | 1.8 | 29 |
| 92 | European Union-28: An annualised cost-of-illness model for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 115, 800-808. | 1.8 | 85 |
| 93 | The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1240-1248. | 1.8 | 64 |
| 94 | The BRIDGE trial: What the hospitalist should know. <i>Journal of Hospital Medicine</i> , 2016, 11, 652-657. | 0.7 | 4 |
| 95 | Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. <i>American Journal of Medicine</i> , 2016, 129, 1001.e9-1001.e18. | 0.6 | 69 |
| 96 | Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115. | 2.5 | 40 |
| 97 | Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2016, 95, 1457-1464. | 0.8 | 48 |
| 98 | Perioperative Management of the Direct Oral Anticoagulants. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1073-1084. | 0.9 | 14 |
| 99 | Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. <i>American Journal of Emergency Medicine</i> , 2016, 34, 19-25. | 0.7 | 3 |
| 100 | Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. <i>American Journal of Medicine</i> , 2016, 129, S54-S63. | 0.6 | 9 |
| 101 | External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. <i>Thrombosis and Haemostasis</i> , 2016, 116, 530-536. | 1.8 | 47 |
| 102 | Cost-of-illness model for venous thromboembolism. <i>Thrombosis Research</i> , 2016, 145, 130-132. | 0.8 | 12 |
| 103 | Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632. | 1.8 | 201 |
| 104 | All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , 2015, 114, 685-694. | 1.8 | 2 |
| 105 | Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 373, 823-833. | 13.9 | 951 |
| 106 | Features of Electronic Health Records Necessary for the Delivery of Optimized Anticoagulant Therapy. <i>Annals of Pharmacotherapy</i> , 2015, 49, 113-124. | 0.9 | 12 |
| 107 | Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated with Different Outcomes Among Patients with Venous Thromboembolism?. <i>Blood</i> , 2015, 126, 1126-1126. | 0.6 | 1 |
| 108 | External Validation of a Risk Assessment Model for Bleeding Risk in Medical Patients: Findings from the Improve Investigators in a Tertiary Health System. <i>Blood</i> , 2015, 126, 748-748. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Direct Oral Anticoagulants. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1333-1351. | 1.1 | 81 |
| 110 | Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 1850-1859. | 1.6 | 234 |
| 111 | External Validation of the Risk Assessment Model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for Medical Patients in a Tertiary Health System. <i>Journal of the American Heart Association</i> , 2014, 3, e001152. | 1.6 | 107 |
| 112 | Treatment and Long-Term Management of Venous Thromboembolism. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 519-536. | 0.7 | 3 |
| 113 | Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure. <i>Circulation</i> , 2014, 130, 410-418. | 1.6 | 53 |
| 114 | 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080. | 1.0 | 2,591 |
| 115 | Venous Thromboembolism Risk in Patients With Inflammatory Bowel Disease: Defining the Benefits of Pharmacologic Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1577. | 2.4 | 1 |
| 116 | External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). <i>Thrombosis and Haemostasis</i> , 2014, 112, 692-699. | 1.8 | 67 |
| 117 | Validating the IMPROVE Venous Thromboembolism (VTE) Risk Score: Retrospective Analysis of Electronic Data From a Large Health System. <i>Chest</i> , 2014, 145, 522A. | 0.4 | 1 |
| 118 | Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Venous Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial. <i>Blood</i> , 2014, 124, 4271-4271. | 0.6 | 0 |
| 119 | Practical issues, limitations, and periprocedural management of the NOACs. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 212-222. | 1.0 | 29 |
| 120 | Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. <i>Thrombosis Research</i> , 2013, 132, 520-526. | 0.8 | 45 |
| 121 | Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2013, 368, 513-523. | 13.9 | 524 |
| 122 | Treatment of Bleeding Complications When Using Oral Anticoagulants for Prevention of Strokes. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2013, 15, 288-298. | 0.4 | 24 |
| 123 | Venous thromboembolism management: where do novel anticoagulants fit?. <i>Current Medical Research and Opinion</i> , 2013, 29, 783-790. | 0.9 | 6 |
| 124 | Antithrombotic Medication Use and Bleeding Risk in Medically Ill Patients After Hospitalization. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 504-512. | 0.7 | 11 |
| 125 | Interruption of Warfarin Anticoagulation for Dental Surgery: Response. <i>Chest</i> , 2013, 144, 1424-1426. | 0.4 | 4 |
| 126 | Venous Thromboembolism Prevention in Hospitalized Medical and Surgical Patients. , 2013, , 741-745. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists. <i>Circulation</i> , 2012, 126, 1630-1639. | 1.6 | 406 |
| 128 | Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1027-1034. | 1.8 | 25 |
| 129 | Perioperative Management of Antithrombotic Therapy. <i>Chest</i> , 2012, 141, e326S-e350S. | 0.4 | 1,461 |
| 130 | Preventing VTE in Outpatients With Cancer. <i>Chest</i> , 2012, 142, 265-266. | 0.4 | 3 |
| 131 | How I treat anticoagulated patients undergoing an elective procedure or surgery. <i>Blood</i> , 2012, 120, 2954-2962. | 0.6 | 331 |
| 132 | Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. <i>Thrombosis and Haemostasis</i> , 2012, 108, 291-302. | 1.8 | 137 |
| 133 | Pro: "Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery" <i>Thrombosis and Haemostasis</i> , 2012, 108, 213-216. | 1.8 | 25 |
| 134 | Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235. | 1.8 | 24 |
| 135 | The use of weighted and scored risk assessment models for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1072-1076. | 1.8 | 40 |
| 136 | Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event. <i>Thrombosis and Haemostasis</i> , 2011, 106, 405-415. | 1.8 | 61 |
| 137 | Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. <i>Chest</i> , 2011, 140, 706-714. | 0.4 | 401 |
| 138 | The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 196-208. | 1.0 | 18 |
| 139 | Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 407-416. | 1.0 | 105 |
| 140 | Factors at Admission Associated With Bleeding Risk in Medical Patients. <i>Chest</i> , 2011, 139, 69-79. | 0.4 | 347 |
| 141 | The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer. <i>Blood</i> , 2011, 118, 542-542. | 0.6 | 3 |
| 142 | Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. <i>Blood</i> , 2011, 118, 545-545. | 0.6 | 1 |
| 143 | Bridging therapy and oral anticoagulation: current and future prospects. <i>Current Opinion in Hematology</i> , 2010, 17, 444-449. | 1.2 | 28 |
| 144 | Risk assessment of venous thromboembolism in hospitalized medical patients. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 419-425. | 1.2 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 192-198. | 1.0 | 15 |
| 146 | Rates of venous thromboembolism occurrence in medical patients among the insured population. <i>Thrombosis and Haemostasis</i> , 2009, 102, 951-957. | 1.8 | 57 |
| 147 | Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 458-464. | 1.0 | 55 |
| 148 | Use of Emerging Oral Anticoagulants in Clinical Practice. <i>Annals of Surgery</i> , 2009, 250, 219-228. | 2.1 | 30 |
| 149 | Perioperative Bridging Therapy With Unfractionated Heparin or Low-Molecular-Weight Heparin in Patients With Mechanical Prosthetic Heart Valves on Long-Term Oral Anticoagulants (from the Tj ETQq1 1 0.784304rgBT /Ozlock 10 | 0.7 | 32 |
| 150 | The Perioperative Management of Antithrombotic Therapy. <i>Chest</i> , 2008, 133, 299S-339S. | 0.4 | 763 |
| 151 | Epidemiology of Venous Thromboembolism in Cardiorespiratory and Infectious Disease. <i>American Journal of Medicine</i> , 2008, 121, 935-942. | 0.6 | 51 |
| 152 | Investigational treatments of venous thromboembolism. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 431-440. | 1.9 | 36 |
| 153 | Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients. <i>Chest</i> , 2007, 132, 936-945. | 0.4 | 446 |
| 154 | Management of Venous Thromboembolism in the Elderly. <i>Drugs and Aging</i> , 2006, 23, 651-671. | 1.3 | 28 |
| 155 | Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. <i>Current Medical Research and Opinion</i> , 2006, 22, 1109-1122. | 0.9 | 49 |
| 156 | Prevention of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 755-766. | 1.5 | 27 |
| 157 | Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients. <i>Chest</i> , 2005, 128, 958-969. | 0.4 | 55 |
| 158 | Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. <i>Thrombosis and Haemostasis</i> , 2005, 94, 750-9. | 1.8 | 173 |
| 159 | Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. <i>Clinical Therapeutics</i> , 2004, 26, 1149-1159. | 1.1 | 72 |
| 160 | Costs and Clinical Outcomes Associated With Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Bridging in Patients Receiving Long-term Oral Anticoagulant Therapy. <i>Chest</i> , 2004, 125, 1642-1650. | 0.4 | 105 |
| 161 | Management of Acute Proximal Deep Vein Thrombosis. <i>Chest</i> , 2002, 122, 108-114. | 0.4 | 111 |